111 related articles for article (PubMed ID: 9286966)
21. Prolongation by captopril of action potential duration in the normal and hypertrophied rat ventricle: direct action or inhibition of the local angiotensin converting enzyme?
Ribuot C; Cardinal R; Gouin L; Moreau P; Godin D; Vermeulen M; de Champlain J; Rochette L; Nadeau R
Cardiovasc Res; 1994 Feb; 28(2):221-7. PubMed ID: 8143304
[TBL] [Abstract][Full Text] [Related]
22. Modulation of adrenergic receptors during left ventricular hypertrophy development and after regression by captopril.
Martínez ML; Fernández-Tomé P; López-Miranda V; Colado MI; Delgado C
J Cardiovasc Pharmacol; 1999 Oct; 34(4):505-11. PubMed ID: 10511124
[TBL] [Abstract][Full Text] [Related]
23. Ventricular fibrillation threshold and local dispersion of refractoriness in isolated rabbit hearts with left ventricular dysfunction.
Burton FL; McPhaden AR; Cobbe SM
Basic Res Cardiol; 2000 Oct; 95(5):359-67. PubMed ID: 11099162
[TBL] [Abstract][Full Text] [Related]
24. Reduction of dispersion of repolarization and prolongation of postrepolarization refractoriness explain the antiarrhythmic effects of quinidine in a model of short QT syndrome.
Milberg P; Tegelkamp R; Osada N; Schimpf R; Wolpert C; Breithardt G; Borggrefe M; Eckardt L
J Cardiovasc Electrophysiol; 2007 Jun; 18(6):658-64. PubMed ID: 17521304
[TBL] [Abstract][Full Text] [Related]
25. New insights into the beneficial electrophysiologic profile of ranolazine in heart failure: prevention of ventricular fibrillation with increased postrepolarization refractoriness and without drug-induced proarrhythmia.
Frommeyer G; Rajamani S; Grundmann F; Stypmann J; Osada N; Breithardt G; Belardinelli L; Eckardt L; Milberg P
J Card Fail; 2012 Dec; 18(12):939-49. PubMed ID: 23207083
[TBL] [Abstract][Full Text] [Related]
26. Arrhythmogenic mechanisms in left ventricular hypertrophy.
Wolk R
Europace; 2000 Jul; 2(3):216-23. PubMed ID: 11227591
[TBL] [Abstract][Full Text] [Related]
27. Ventricular hypertrophy amplifies transmural dispersion of repolarization by preferentially increasing the late sodium current in endocardium.
Guo D; Yu M; Liu Q; Cox RH; Liu T; Yan GX
J Electrocardiol; 2014; 47(5):642-8. PubMed ID: 24813353
[TBL] [Abstract][Full Text] [Related]
28. Regression of chronic L -NAME-treatment-induced left ventricular hypertrophy: effect of captopril.
Bernátová I; Pechánová O; Pelouch V; Simko F
J Mol Cell Cardiol; 2000 Feb; 32(2):177-85. PubMed ID: 10722795
[TBL] [Abstract][Full Text] [Related]
29. Regression of myocardial fibrosis in hypertensive heart disease: diverse effects of various antihypertensive drugs.
Brilla CG
Cardiovasc Res; 2000 May; 46(2):324-31. PubMed ID: 10773237
[TBL] [Abstract][Full Text] [Related]
30. [Regression of cardiac hypertrophy in hypertensive patients treated with captopril].
Olivan Martínez J; Hoyos Jiménez M; Moreno Alba R; Justo Alpañes E; Pérez Cano R
An Med Interna; 1994 May; 11(5):227-31. PubMed ID: 8061137
[TBL] [Abstract][Full Text] [Related]
31. [Arrhythmia risk in left ventricular hypertrophy].
Perings C; Hennersdorf M; Vester EG; Strauer BE
Z Kardiol; 2000; 89 Suppl 3():36-43. PubMed ID: 10810783
[TBL] [Abstract][Full Text] [Related]
32. Electrophysiologic effects of left ventricular hypertrophy in the intact cat.
Shechter JA; O'Connor KM; Friehling TD; Mark R; Uboh C; Kowey PR
Am J Hypertens; 1989 Feb; 2(2 Pt 1):81-5. PubMed ID: 2521793
[TBL] [Abstract][Full Text] [Related]
33. The potential mechanisms of reduced incidence of ventricular fibrillation as the presenting rhythm in sudden cardiac arrest.
Wang H; Tang W; Ristagno G; Li Y; Sun S; Wang T; Weil MH
Crit Care Med; 2009 Jan; 37(1):26-31. PubMed ID: 19050623
[TBL] [Abstract][Full Text] [Related]
34. Acute filling pattern changes of the failing left ventricle after captopril as related to ventricular structure.
Barbier P; Tamborini G; Alioto G; Pepi M
Cardiology; 1996; 87(2):153-60. PubMed ID: 8653733
[TBL] [Abstract][Full Text] [Related]
35. Improvement of diastolic function after regression of left ventricular hypertrophy.
Teniente-Valente R; Solorio S; Vargas-Salado E; Aguirre-Vázquez C; Hernández-González MA; Olvera-Lopez JA; Rodríguez-Mariscal L; Luna-Ruiz MA; Guillén Contreras JM; Murillo Ortiz BO
Arch Cardiol Mex; 2008; 78(4):392-9. PubMed ID: 19205547
[TBL] [Abstract][Full Text] [Related]
36. The role of angiotensin receptor-1 blockade on electromechanical changes induced by left ventricular hypertrophy and its regression.
Gray RP; Turner MA; Sheridan DJ; Fry CH
Cardiovasc Res; 2007 Feb; 73(3):539-48. PubMed ID: 17174288
[TBL] [Abstract][Full Text] [Related]
37. Modification by glibenclamide of the electrophysiological consequences of myocardial ischaemia in dogs and rabbits.
Smallwood JK; Ertel PJ; Steinberg MI
Naunyn Schmiedebergs Arch Pharmacol; 1990 Aug; 342(2):214-20. PubMed ID: 2122259
[TBL] [Abstract][Full Text] [Related]
38. Reduction in myocardial collagen cross-linking parallels left ventricular dilatation in rat models of systolic chamber dysfunction.
Woodiwiss AJ; Tsotetsi OJ; Sprott S; Lancaster EJ; Mela T; Chung ES; Meyer TE; Norton GR
Circulation; 2001 Jan; 103(1):155-60. PubMed ID: 11136701
[TBL] [Abstract][Full Text] [Related]
39. Uni- or bi-ventricular hypertrophy and susceptibility to drug-induced torsades de pointes.
Panyasing Y; Kijtawornrat A; Del Rio C; Carnes C; Hamlin RL
J Pharmacol Toxicol Methods; 2010; 62(2):148-56. PubMed ID: 20435152
[TBL] [Abstract][Full Text] [Related]
40. Nitrendipine vs. captopril in essential hypertension: effects on circadian blood pressure and left ventricular hypertrophy.
Machnig T; Henneke KH; Engels G; Pongratz G; Schmalzl M; Gellert J; Bachmann K
Cardiology; 1994; 85(2):101-10. PubMed ID: 7954561
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
